Sofinnova Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Sofinnova Investments’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-276,628	Closed	-$4.24M	–	72
2020 Q3	$4.24M	Sell	276,628 -533,175	-66%	-$10M	0.31%	50
2020 Q2	$20.6M	Sell	809,803 -112,897	-12%	-$2.36M	1.3%	23
2020 Q1	$14.3M	Hold	922,700	–	–	1.32%	18
2019 Q4	$10.2M	Hold	922,700	–	–	0.74%	29
2019 Q3	$7.85M	Hold	922,700	–	–	0.71%	32
2019 Q2	$12.5M	Hold	922,700	–	–	1.15%	19
2019 Q1	$16.7M	Hold	922,700	–	–	1.61%	14
2018 Q4	$25.9M	Hold	922,700	–	–	3.23%	11
2018 Q3	$23.5M	Hold	922,700	–	–	2.1%	12
2018 Q2	$16M	Buy	+922,700	New	+$16.7M	1.81%	13

Other funds holding KNSA

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Sofinnova Investments's KNSA Position: Q4 2020 in Review

Sofinnova Investments sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 276,628 shares — an estimated $4.24M sold.

Sofinnova Investments first reported a position in KNSA in Q2 2018 and held it in 10 quarters. The position peaked at $25.9M in Q4 2018. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

Sofinnova Investments reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Sofinnova Investments sold 276,628 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $4.24M.
Sofinnova Investments first reported a position in Kiniksa Pharmaceuticals in Q2 2018 and held it in 10 quarters.
Sofinnova Investments's Kiniksa Pharmaceuticals position peaked at $25.9M in Q4 2018.
108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Sofinnova Investments's 13F filing for Q4 2020, filed 16 Feb 2021.